Mepolizumab with smaller or larger sinus surgery for chronic rhinosinusitis with nasal polyps
Compares mepolizumab with simple polyp removal or wider sinus surgery in adults with nasal polyps.
Key facts
- Who runs it
- Eye & ENT Hospital of Fudan University
- Where
- China17 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 360 people, planned
- Started
- 8 Oct 2025
- Expected to end
- 10 Oct 2031
- Type of study
- Interventional, 3 groups
- Treatments tested
- Mepolizumab
- Simple Polypectomy
- Extended Endoscopic Sinus Surgery
- Record updated
- 1 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic rhinosinusitis with nasal polyps (long-lasting sinus swelling with growths in the nose). Everyone gets the anti-IL-5 drug mepolizumab, alone, with simple polyp removal, or with extended sinus surgery.
- Age
- 18 Years to 75 Years
- Sex
- All
- Disease stage
- Polyps in both sides of the nose seen by endoscopy (a camera exam), with a polyp score of ≥4 in total (≥2 per side). Blocked nose for >3 months, with a blockage score of ≥2 and/or a loss-of-smell score of ≥2.
- Earlier treatment
- Standard medicine did not help after 4 weeks, including nose steroid sprays for >4 weeks. People who had sinus surgery for this disease before cannot join. No steroid tablets within 1 month.
- Biomarker or test result
- Signs of type 2 inflammation: eosinophils (a type of white blood cell) in polyp tissue >55/HPF or >27% of inflammatory cells, or blood eosinophils ≥6.9% (without asthma) or ≥3.7% (with asthma).
Main reasons for not taking part
- Cystic fibrosis, Young's syndrome, Kartagener syndrome, antrochoanal polyp or rhinitis medicamentosa
- HIV infection, or a parasite infection within 6 months
- Allergy to monoclonal antibodies or anti-IL-5 drugs
- Pregnancy, planning a pregnancy, or breastfeeding
- Uncontrolled body-wide diseases, or a strongly bent nasal wall (septum)
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Endoscopy shows bilateral nasal polyps, with bilateral NPS ≥4 (≥2 per side)
- Nasal obstruction symptoms >3 months, nasal obstruction score ≥2 (total 3 points) and/or hyposmia ≥2 (maximum 3 points)
- Evidence of type 2 inflammation: Nasal polyp tissue Eos >55/HPF or >27% of inflammatory cells; or Peripheral blood Eos ≥6.9% (without asthma) or ≥3.7% (with asthma) Note: Meet any 2 of the above 3 criteria
- Failure after 4 weeks of standard medical therapy including: Intranasal corticosteroids >4 weeks; Other agents (oral steroids, macrolides, antihistamines, leukotriene receptor antagonists, decongestants, antibiotics) permitted as needed
Who cannot take part
- History of hypersensitivity to investigational drugs (except aspirin intolerance)
- Oral steroid therapy within 1 month
- Have a history of previous sinus surgery for CRSwNP
- Cystic fibrosis, Young's syndrome, Kartagener syndrome, antrochoanal polyp, or rhinitis medicamentosa
- Acute upper respiratory infection within 2 weeks
- HIV infection
- Parasitic infection within 6 months
- Hypersensitivity to monoclonal antibodies or anti-IL-5 agents
- Uncontrolled systemic diseases
- Asthma exacerbation within 1 month
- Pregnancy planning, current pregnancy, or lactation
- Significant septal deviation affecting unilateral ventilation (mild deviation allowed)
- Investigator judgment of unsuitability for cohort study
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study compares two surgical approaches combined with anti-IL-5 therapy in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Patients will be randomly assigned to one of the three groups: (1) anti-IL-5 alone, (2) anti-IL-5 with simple polyp removal, or (3) anti-IL-5 with extended sinus surgery. The aim of this study is to see if a less invasive surgery (simple polyp removal) with anti-IL-5 works as well as more extensive surgery with anti-IL-5. Participants will be followed for 1 to 3 years.
The 3 groups in the trial
- Anti-IL-5 MonotherapyTreatment being tested
Mepolizumab 100mg subcutaneously every 4 weeks for 24 weeks
Treatment: Mepolizumab
- Anti-IL-5 + Simple PolypectomyTreatment being tested
Combined therapy: A 100 mg dose of mepolizumab is initiated subcutaneously 2 weeks after simple polypectomy. Mepolizumab will be administered subcutaneously every 4 weeks for 24 weeks.
Treatment: Mepolizumab and Simple Polypectomy
- Anti-IL-5 + Extended Endoscopic Sinus SurgeryTreatment being tested
Combined therapy: A 100 mg dose of mepolizumab is initiated subcutaneously 2 weeks after Extended Endoscopic Sinus Surgery. Mepolizumab will be administered subcutaneously every 4 weeks for 24 weeks.
Treatment: Mepolizumab and Extended Endoscopic Sinus Surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Anti-IL-5 Therapy Combined With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery in Patients With CRSwNP: A Multicenter Randomized Controlled Trial
- Plain-language title
- Mepolizumab with smaller or larger sinus surgery for chronic rhinosinusitis with nasal polypsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07200336, who can take part
- Record updated
- 1 October 2025